Home/Alpha-9 Oncology/Kuo-Shyan Lin, PhD

KL

Kuo-Shyan Lin, PhD

Co-Founder

Alpha-9 Oncology

Therapeutic Areas

Alpha-9 Oncology Pipeline

Drug	Indication	Phase
A9-3202	Not Specified (Imaging Agent)	Phase 1
A9-3408	Not Specified	Phase 1

Leadership Team at Alpha-9 Oncology

Paul Blanchfield

Chief Executive Officer

François Bénard, MD

David Perrin, PhD

View full Alpha-9 Oncology profile